MLH1 Antibody (G168-15): sc-56161
- MLH1 Antibody (G168-15) is a mouse monoclonal IgG1, cited in 6 publications, provided at 250 µl
- raised against full length MLH1 of human origin
- recommended for detection of MLH1 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for MLH1 Antibody (G168-15). This work is in progress.
QUICK LINKS
MLH1 Antibody (G168-15) is a mouse monoclonal IgG1 antibody that detects MLH1 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). MLH1 plays a crucial role in the DNA mismatch repair (MMR) process, which is vital for maintaining genetic stability by correcting DNA replication errors. MLH1 (G168-15) antibody helps identify deficiencies linked to various human cancers, particularly due to mutations or epigenetic silencing of the MLH1 gene. MLH1 is predominantly located in the nucleus, where MLH1 forms a complex with other MMR proteins to identify and repair mismatched DNA bases, thereby preventing mutations that could lead to tumorigenesis. MLH1 expression is notably observed in various tissues, including lymphocytes, heart, colon, breast, lung, spleen, testis, prostate, thyroid, and gall bladder, with MLH1 methylation being a common feature in several ovarian tumors. Loss of MLH1 expression is associated with a mutated phenotype and microsatellite instability, which are significant indicators of cancer predisposition. In hereditary nonpolyposis colorectal cancer (HNPCC), pathogenic mutations in the MLH1 gene highlight MLH1′s importance in cancer risk assessment. Notably, certain cancer cell lines, such as leukemia CCRF-CEM and colon HCT 116, exhibit complete deficiency of MLH1, while MLH1 is expressed in a significant percentage of melanomas and squamous cell carcinomas, underscoring MLH1′s relevance in cancer biology and potential as a therapeutic target.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MLH1 Antibody (G168-15) References:
- Assessing the link between BACH1/FANCJ and MLH1 in DNA crosslink repair. | Cantor, SB. and Xie, J. 2010. Environ Mol Mutagen. 51: 500-7. PMID: 20658644
- Role of MLH1 methylation in esophageal cancer carcinogenesis and its clinical significance. | Li, J., et al. 2018. Onco Targets Ther. 11: 651-663. PMID: 29440913
- Regulation of the MLH1-MLH3 endonuclease in meiosis. | Cannavo, E., et al. 2020. Nature. 586: 618-622. PMID: 32814904
- Expressing MLH1 in HCT116 cells increases cellular resistance to radiation by activating the PRKAC. | Huang, Y., et al. 2022. Exp Biol Med (Maywood). 247: 426-432. PMID: 34787019
- MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma. | Manzoor, S., et al. 2022. Neoplasia. 24: 76-85. PMID: 34952246
- Mlh1 interacts with both Msh2 and Msh6 for recruitment during mismatch repair. | DuPrie, ML., et al. 2022. DNA Repair (Amst). 119: 103405. PMID: 36122480
- MLH1 Loss in Primary Prostate Cancer. | Nourmohammadi Abadchi, S., et al. 2023. JCO Precis Oncol. 7: e2200611. PMID: 37196219
- Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques. | Deycmar, S., et al. 2024. J Transl Med. 22: 292. PMID: 38504345
- TDP43 interacts with MLH1 and MSH6 proteins in a DNA damage-inducible manner. | Provasek, VE., et al. 2024. Mol Brain. 17: 32. PMID: 38840222
- MLH1 Inhibits Metastatic Potential of Pancreatic Ductal Adenocarcinoma via Downregulation of GPRC5C. | Liu, WJ., et al. 2024. Lab Invest. 104: 102107. PMID: 38964504
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MLH1 Antibody (G168-15) | sc-56161 | 250 µl | $322.00 |